Compare Nike Inc (NKE) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs Stryker Corporation — how do they compare? Nike Inc trades at $40.58 (market cap $61.30B), while Stryker Corporation trades at $346.82 (market cap $133.54B). The key difference: Stryker Corporation is far larger — about 2.2× Nike Inc's market cap, and Nike Inc pays the higher dividend (3.97%). Which is the better fit depends on your goals.
| NKE | SYK | |
|---|---|---|
Market Cap | $61.30B | $133.54B |
Volume | 8,887,180 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $79.17 | $394.34 |
52-Week Low | $40.75 | $282.58 |
Enterprise Value | $63.30B | $145.01B |
Dividend Yield | 3.97% | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $42.11, up 0.98% on the day, showing resilience amid a challenging period. The stock faces bearish technical signals but maintains strong profitability metrics including 42.91% gross margin and 22.14% ROE. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.72 significantly exceeding the $0.11 forecast. However, revenue declined to $46.31B in 2025 from $51.4B in 2024, reflecting ongoing business headwinds.
Nike's investment case balances strong brand value and consistent earnings beats against revenue pressures and competitive challenges. The consensus price target of $50.45 suggests 20% upside potential, though technical indicators remain bearish. Key risks include China market weakness and inventory management issues, while opportunities lie in digital transformation and product innovation driving future growth.
Stryker (SYK) trades at $345.86, up slightly by 0.01% today, with a bullish technical signal and strong analyst support. The company reported a Q2 2026 earnings beat with $3.69 EPS versus $3.49 expected, driven by 9% organic sales growth and recovery from a cyber incident. Fundamentals show robust profitability with a 14.43% net income margin and 16.51% ROE, though valuation ratios like a P/E of 36.08 are elevated.
Outlook remains positive with raised guidance and new product launches like Mako RPS expanding market reach. Key risks include execution challenges post-cyberattack and competitive pressures. The consensus price target of $379.44 implies ~10% upside, supported by 74% buy ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
